BIOGEN INC. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
BIOGEN INC. (BIIB) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $11.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-06
- BIOGEN INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $11.80M, a 195.00% increase from fiscal 2024.
- BIOGEN INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $4.00M, a 64.60% decline from fiscal 2023.
- BIOGEN INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $11.30M, a 5550.00% increase from fiscal 2022.
- BIOGEN INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $200.00K, a 95.45% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month as first filed |
|---|---|---|
| 2025-12-31 | $11.80M 10-K · filed 2026-02-06 | |
| 2024-12-31 | $4.00M 10-K · filed 2026-02-06 | |
| 2023-12-31 | $11.30M 10-K · filed 2026-02-06 | |
| 2022-12-31 | $200.00K 10-K · filed 2025-02-12 | |
| 2021-12-31 | $4.40M 10-K · filed 2024-02-14 | |
| 2020-12-31 | $35.90M 10-K · filed 2023-02-15 | |
| 2019-12-31 | $35.90M 10-K · filed 2022-02-03 | $3.60M 10-K · filed 2020-02-06 |
| 2018-12-31 | $4.70M 10-K · filed 2020-02-06 | |
| 2017-12-31 | $44.60M 10-K · filed 2020-02-06 | |
| 2016-12-31 | $64.30M 10-K · filed 2019-02-06 | |
| 2015-12-31 | $42.50M 10-K · filed 2018-02-01 | |
| 2014-12-31 | $60.50M 10-K · filed 2017-02-02 | |
| 2013-12-31 | $5.40M 10-K · filed 2016-02-03 | |
| 2012-12-31 | $800.00K 10-K · filed 2015-02-04 | |
| 2011-12-31 | $29.80M 10-K · filed 2014-02-06 | |
| 2010-12-31 | $20.30M 10-K · filed 2013-02-05 | -$20.30M 10-K · filed 2011-02-04 |
| 2009-12-31 | $105.60M 10-K · filed 2012-02-03 | -$105.60M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |